GlassScriptPhysician profile
Alexander J Chen
NPI 1750543476
$6,127.88
in general payments reported to CMS, 2019-2025
22 companies · $498 in 2025
The $498 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $854 · 2021: $1,018 · 2022: $1,247 · 2023: $511 · 2024: $1,520 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681 · Travel and Lodging: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.89 |
| Travel and Lodging | $848.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,776.06 | 2019-2023 | Proclaim |
| Boston Scientific Corporation | $1,230.33 | 2019-2024 | Intracept, Na |
| Medtronic, INC. | $868.06 | 2021-2025 | Kyphon Express II Kyphopak Tray, Mazor X System, Osteocool Rf Ablation System |
| Teva Pharmaceuticals USA, INC. | $514.58 | 2019-2023 | Ajovy |
| Si-Bone, INC. | $310.45 | 2020-2021 | |
| Nevro Corp. | $194.17 | 2022-2023 | Senza |
| Abbvie INC. | $181.59 | 2021-2023 | Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $177.01 | 2020-2021 | |
| Amgen INC. | $155.09 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $101.50 | 2020-2021 | |
| Globus Medical, INC. | $101.08 | 2025 | Senza |
| Relievant Medsystems, INC. | $90.70 | 2020-2022 | |
| La Jolla Pharmaceutical Company | $85.37 | 2019 | |
| Scilex Pharmaceuticals INC. | $68.53 | 2021-2023 | Ztlido |
| Grt US Holding, INC. | $61.57 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $58.30 | 2021-2023 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $51.10 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $29.72 | 2025 | |
| Allergan, INC. | $24.39 | 2020-2022 | |
| Almatica Pharma LLC | $19.32 | 2021 | |
| Lilly USA, LLC | $16.06 | 2021 | |
| Assertio Therapeutics, INC. | $12.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.